Efficacy of an antagonistic Anti-CD40 monoclonal antibody, HCD122 (CHIR-12.12), in preclinical models of human Non-Hodgkin's lymphoma and Hodgkin's disease.

被引：1
|
作者：
Long, Li
Patawaran, Montesa
Tong, Xia
Kantak, Seema
Aukerman, Sharon L.
Pryer, Nancy
Luqman, Mohammad
机构：
[1] Novartis Inst Biomed Res, Emeryville, CA USA
[2] LLC, XOMA US, Berkeley, CA USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.230.230
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
230
引用
收藏
页码：72A / 72A
页数：1
相关论文
共 50 条
  • [41] Tc-99m-CD19 monoclonal antibody is not useful for imaging of B cell non-Hodgkin's lymphoma
    Vervoordeldonk, SF
    Heikens, J
    Goedemans, WT
    Merle, PA
    vondemBorne, AEGK
    vanRoyen, EA
    SlaperCortenbach, ICM
    vanOers, RHJ
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 42 (05) : 291 - 296
  • [42] Elevation of activated platelet-dependent chemokines in patients with anti-CD20 monoclonal antibody (Rituximab)-treated non-Hodgkin's lymphoma
    Nomura, Shosaku
    Ishii, Kazuyoshi
    Kamitsuji, Yuka
    Uoshima, Nobuhiko
    Ishikawa, Emiko
    Kitayama, Hitoshi
    Hayashi, Kunio
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2007, 13 (02) : 206 - 212
  • [43] Radioimmunotherapy (RIT) of non-Hodgkin's lymphoma (NHL) with I-131 anti-CD20 monoclonal antibody (Bexxar™).: Preliminary results
    Antonescu, C
    Buchegger, F
    Kosinski, M
    Ketterer, N
    Kovacsovics, T
    Helg, C
    Delaloye, AB
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 980 - 980
  • [44] Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
    Piro, LD
    White, CA
    Grillo-López, AJ
    Janakiraman, N
    Saven, A
    Beck, TM
    Varns, C
    Shuey, S
    Czuczman, M
    Lynch, JW
    Kolitz, JE
    Jain, V
    ANNALS OF ONCOLOGY, 1999, 10 (06) : 655 - 661
  • [45] Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma:: Results of a phase II trial of rituximab
    Davis, TA
    White, CA
    Grillo-López, AJ
    Velásquez, WS
    Link, B
    Maloney, DG
    Dillman, RO
    Williams, ME
    Mohrbacher, A
    Weaver, R
    Dowden, S
    Levy, R
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) : 1851 - 1857
  • [46] A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas
    Feugier, Pierre
    FUTURE ONCOLOGY, 2015, 11 (09) : 1327 - 1342
  • [47] A humanizedaAnti-CD40 monoclonal antibody (SGN-40) demonstrates antitumor activity in non-Hodgkin's lymphoma: Initiation of a phase I clinical trial.
    Drachman, JG
    Law, CL
    Furman, RR
    Baumgartner, K
    Kunkel, LA
    Ryan, K
    Miller, D
    McDonald, M
    Grewal, IS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 578S - 578S
  • [48] Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma
    Leonard, JP
    Coleman, M
    Ketas, JC
    Chadburn, A
    Ely, S
    Furman, RR
    Wegener, WA
    Hansen, HJ
    Ziccardi, H
    Eschenberg, M
    Gayko, U
    Cesano, A
    Goldenberg, DM
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) : 3051 - 3059
  • [49] Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma
    Kato, Jason
    O'Donnell, Robert T.
    Abuhay, Mastewal
    Tuscano, Joseph M.
    ONCOIMMUNOLOGY, 2012, 1 (09): : 1469 - 1475
  • [50] Phase I/II trial epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's lymphoma (NHL).
    Leonard, JP
    Coleman, M
    Matthews, JC
    Chadburn, A
    Wegener, WA
    Hansen, HJ
    Ziccardi, H
    Kapushoc, H
    Gayko, U
    Cesano, A
    Fields, SZ
    Goldenberg, DM
    BLOOD, 2002, 100 (11) : 358A - 358A
12345